OBSOLETE: Inherited predisposition to essential thrombocythemia Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

📰

2Recent news

Regulatory Watchboard

No FDA or trial events recorded yet for OBSOLETE: Inherited predisposition to essential thrombocythemia.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for OBSOLETE: Inherited predisposition to essential thrombocythemia.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Vonjo

(PACRITINIB)Orphan drugaccelerated

Sobi, Inc.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for OBSOLETE: Inherited predisposition to essential thrombocythemia.
Search all trials →

Search clinical trials for OBSOLETE: Inherited predisposition to essential thrombocythemia →

Recent News & Research

2 articles

BREAKINGFDA

FDA Approves VONJO

VONJO (PACRITINIB CITRATE) received FDA approval.

Read ↗

BREAKINGFDA

FDA Approves OJJAARA

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) received FDA approval.

Read ↗

Browse all OBSOLETE: Inherited predisposition to essential thrombocythemia news →

Specialist Network

No specialists currently listed for OBSOLETE: Inherited predisposition to essential thrombocythemia.

View all OBSOLETE: Inherited predisposition to essential thrombocythemia specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰